An observational study in Hydroxychloroquine Retinopathy, sponsored by Sohag University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Sohag University · Observational
This study aims to evaluate retinal and choroidal microvascular changes using optical coherence tomography angiography (OCTA) in patients receiving hydroxychloroquine therapy. Hydroxychloroquine is commonly used in the treatment of autoimmune diseases and may cause retinal toxicity with long-term use. OCTA is a non-invasive imaging modality that allows detailed assessment of retinal vascular changes.
Hydroxychloroquine is widely prescribed for the management of autoimmune and rheumatologic diseases. Long-term use of hydroxychloroquine has been associated with retinal toxicity, which may lead to irreversible visual impairment if not detected early. Conventional screening methods include fundus examination, automated visual field testing, and spectral-domain optical coherence tomography.
Optical coherence tomography angiography (OCTA) is a non-invasive imaging technique that enables quantitative and qualitative assessment of retinal and choroidal microvasculature. This study is designed to evaluate OCTA parameters in patients receiving hydroxychloroquine therapy.
Patients undergoing hydroxychloroquine treatment will be evaluated using OCTA imaging. Retinal vascular parameters will be analyzed and correlated with clinical variables such as duration of treatment and cumulative hydroxychloroquine dose. The findings of this study may contribute to improved understanding of early microvascular changes associated with hydroxychloroquine exposure and the potential role of OCTA in retinal toxicity screening.
Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study includes adults receiving hydroxychloroquine therapy for autoimmune diseases and a control group of healthy volunteers. The aim is to evaluate retinal microvascular changes using OCTA imaging.
Exclusion Criteria:
Superficial Capillary Plexus Vessel Density (SCP)
Measurement of superficial capillary plexus vessel density using optical coherence tomography angiography (OCTA) in patients receiving hydroxychloroquine therapy.
Time frame: Day 1
Deep Capillary Plexus Vessel Density (DCP)
Measurement of deep capillary plexus vessel density using optical coherence tomography angiography (OCTA) in patients receiving hydroxychloroquine therapy.
Time frame: Day 1
No study locations are listed for this record.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sohag University